Przejdź do zawartości
Merck

LC/MS Analysis of Plasma Samples on Ascentis® Express C18 Showing Baseline Improvements after Phospholipid Removal using HybridSPE®-Phospholipid

LC/MS Analysis of Plasma Samples on Ascentis® Express C18 Showing Baseline Improvements after Phospholipid Removal using HybridSPE®-Phospholipid application for SPE, application for LC-MS

Materiały

kolumna analityczna

Numer produktu
Opis
Cennik

Ascentis® Express C18, 2.7 μm HPLC Column

2.7 μm particle size, L × I.D. 5 cm × 2.1 mm

probówka lub płytka SPE

Numer produktu
Opis
Cennik

HybridSPE®-Phospholipid

96-well Plate, bed wt. 50 mg, volume 2 mL, pk of 1

CONDITIONS

sample preparation

SPE (Solid Phase Extraction)

sample/matrix

rat plasma

SPE well plate

HybridSPE-Precipitation 96-well Plate, 50 mg/well (575656-U)

sample addition

100 μL rat plasma followed by 300 μL 1% formic acid in acetonitrile

elution

apply vacuum

column

Ascentis Express C18, 5 cm x 2.1 mm I.D., 2.7 μm particles (53822-U)

mobile phase

[A] 10 mM ammonium acetate; [B] 10 mM ammonium acetate in acetonitrile

gradient

0 min - 95% (A); 10 min - 50% (A); 18 min - 50% (A); 18.1 min - 95% (A); 22 min - 95% (A)

flow rate

0.5 mL/min

column temp.

35 °C

detector

ABI 3200QT; ESI (+), MRM (184/103 m/z)

injection

5 μL

Opis

Zastosowanie

HybridSPE-Precipitation:
Precipitate
proteins by first adding 100 μL rat plasma to the HybridSPE-PPT plate followed by 300 μL 1% formic acid in acetonitrile. Do not apply vacuum.
Mix by vortexing the HybridSPE-PPT plate briefly.
Apply vacuum using a 96-well vacuum manifold and collect the resulting eluate for analysis.

Standard Protein Precipitation:
Combine
100 μL rat plasma with 300 μL 1% formic acid in acetonitrile.
Mix by vortexing and centrifuge.
Isolate resulting supernatant for analysis.

Informacje prawne

Ascentis is a registered trademark of Merck KGaA, Darmstadt, Germany
HybridSPE is a registered trademark of Merck KGaA, Darmstadt, Germany